O
Ocelot Bio
About Ocelot Bio
Ocelot Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from severe liver diseases, particularly those with decompensated advanced cirrhosis. This condition often leads to life-threatening complications such as hepatorenal syndrome with acute kidney injury (HRS AKI) and ascites. The company’s mission is to improve the quality of life and outcomes for these patients through groundbreaking therapeutic interventions.
Read full description
Ocelot Bio operates in the biopharmaceutical market, focusing on end-stage liver disease (ESLD). Their primary clients are healthcare providers and patients who are in dire need of advanced medical treatments for severe liver conditions. The company is committed to addressing the unmet medical needs of these patients by developing and bringing to market novel therapeutics that offer hope for a healthier future.
The business model of Ocelot Bio revolves around research and development (R&D) of new drugs. As a clinical-stage company, they invest heavily in scientific research to discover and develop new treatments. Once these treatments are proven effective through clinical trials, they seek regulatory approval to bring these drugs to market. Revenue is generated through the sale of these approved therapeutics, partnerships with larger pharmaceutical companies, and potentially through licensing agreements.
In summary, Ocelot Bio is a forward-thinking biopharmaceutical company focused on creating life-changing treatments for patients with severe liver diseases. By leveraging their unique capabilities and urgent approach, they aim to provide innovative solutions that significantly improve patient outcomes.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- San Diego, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 56.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2022 | $36M | $144M | Vivo Capital · RA Capital Management · Venrock | ↗ |
| LATE VCOther financing | Apr 2021 | $36M | $144M | Undisclosed | — |
Growth signals
Latest recorded traffic for Ocelot Bio is 150 monthly website visits, down 77.9% over the last three months. Ocelot Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ocelot Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ocelot Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.